Atea Pharmaceuticals Stock Today
| AVIR Stock | USD 3.15 0.02 0.63% |
PerformanceVery Weak
| Odds Of DistressLow
|
Atea Pharmaceuticals is selling at 3.15 as of the 21st of March 2025; that is 0.63 percent decrease since the beginning of the trading day. The stock's lowest day price was 3.15. Atea Pharmaceuticals has only a 6 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of October 2020 | Category Healthcare | Classification Health Care |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. The company has 85.53 M outstanding shares of which 2.95 M shares are presently shorted by private and institutional investors with about 8.71 trading days to cover. More on Atea Pharmaceuticals
Moving together with Atea Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Atea Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAtea Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Atea Pharmaceuticals' financial leverage. It provides some insight into what part of Atea Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atea Pharmaceuticals (AVIR) is traded on NASDAQ Exchange in USA. It is located in 225 Franklin Street, Boston, MA, United States, 02110 and employs 56 people. Atea Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 271.11 M. Atea Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 85.53 M outstanding shares of which 2.95 M shares are presently shorted by private and institutional investors with about 8.71 trading days to cover.
Atea Pharmaceuticals currently holds about 684.48 M in cash with (135.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Atea Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAtea Pharmaceuticals holds a total of 85.53 Million outstanding shares. The majority of Atea Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Atea Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Atea Pharmaceuticals. Please pay attention to any change in the institutional holdings of Atea Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Atea Ownership Details
Atea Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Almitas Capital Llc | 2024-12-31 | 752 K | |
| Northern Trust Corp | 2024-12-31 | 704.9 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 659.5 K | |
| Federated Hermes Inc | 2024-12-31 | 582.9 K | |
| Newtyn Management Llc | 2024-12-31 | 580 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 567 K | |
| Two Sigma Advisers, Llc | 2024-12-31 | 493.6 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 409.3 K | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 390.9 K | |
| Blackrock Inc | 2024-12-31 | 9.1 M | |
| Bml Capital Management Llc | 2024-12-31 | 7.6 M |
Atea Pharmaceuticals Historical Income Statement
Atea Stock Against Markets
Atea Pharmaceuticals Corporate Management
| CPA CPA | Exec Officer | Profile | |
| XiaoJian Zhou | Executive Development | Profile | |
| Jayanthi Wolf | Executive Affairs | Profile | |
| Wayne CPA | Executive Officer | Profile | |
| Ariyapadi Krishnaraj | Vice Marketing | Profile | |
| JeanPierre Sommadossi | Chairman, Founder | Profile | |
| John Vavricka | Chief Officer | Profile |
Already Invested in Atea Pharmaceuticals?
The danger of trading Atea Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atea Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atea Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atea Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.